Parkinson's disease and inflammatory changes

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Neurotoxicity research

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/BF03033170PMID 14715444
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Activation of microglia by human neuromelanin is NF‐κB‐dependent and involves p38 mitogen‐activated protein kinase: implications for Parkinson's disease

  2003cited by this paper
• Pathogenic role of glial cells in Parkinson's disease

  2003cited by this paper
• Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration

  2003cited by this paper
• Role of Microglia in Inflammation-Mediated Neurodegenerative Diseases: Mechanisms and Strategies for Therapeutic Intervention

  2003cited by this paper
• Thrombin induces in vivo degeneration of nigral dopaminergic neurones along with the activation of microglia

  2003cited by this paper
• Neuroinflammatory processes in Parkinson's disease

  2003cited by this paper
• Blood Vessels And Neurodegeneration In Parkinson’s Disease

  2002cited by this paper
• Clotting Factors Build Blood Vessels

  2001cited by this paper
• Inflammation in Parkinson's disease.

  2001cited by this paper
• Cytokine-mediated inflammation and signaling in the intact central nervous system.

  2001influential reference
• Inflammation in Parkinson's disease.

  2001cited by this paper
• Inhibition of the cyclooxygenase isoenzymes COX‐1 and COX‐2 provide neuroprotection in the MPTP‐mouse model of Parkinson's disease

  2001cited by this paper
• Microglial Activation and Dopaminergic Cell Injury: An In Vitro Model Relevant to Parkinson's Disease

  2001cited by this paper
• Tumor necrosis factor-alpha: a potentially neurodestructive cytokine produced by glia in the human glaucomatous optic nerve head.

  2000cited by this paper
• Tumor angiogenesis: past, present and the near future.

  2000cited by this paper
• Tumor necrosis factor‐α: A potentially neurodestructive cytokine produced by glia in the human glaucomatous optic nerve head

  2000cited by this paper
• The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse.

  1999influential reference
• Blood vessels change in the mesencephalon of patients with Parkinson's disease.

  1999cited by this paper
• Increase in level of tumor necrosis factor (TNF)-α in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic l-DOPA on the TNF-α induction

  1999cited by this paper
• Blood vessels change in the mesencephalon of patients with Parkinson's disease.

  1999cited by this paper
• Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure

  1999influential reference
• Molecular and biological properties of vascular endothelial growth factor

  1999cited by this paper
• Increase in level of tumor necrosis factor (TNF)-alpha in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic L-DOPA on the TNF-alpha induction.

  1999cited by this paper
• Detailed in vivo analysis of interferon-gamma induced major histocompatibility complex expression in the the central nervous system: astrocytes fail to express major histocompatibility complex class I and II molecules.

  1999cited by this paper
• Structure, expression and receptor-binding properties of novel vascular endothelial growth factors.

  1999cited by this paper
• Tumor stroma.

  1999cited by this paper
• Involvement of platelets in tumour angiogenesis?

  1998cited by this paper
• Interferon-γ in Progression to Chronic Demyelination and Neurological Deficit Following Acute EAE ☆

  1998cited by this paper
• Interferon-gamma in progression to chronic demyelination and neurological deficit following acute EAE.

  1998cited by this paper
• A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF.

  1998cited by this paper
• Understanding cell death in parkinson's disease

  1998cited by this paper
• Glial cells and inflammation in parkinson's disease: A role in neurodegeneration?

  1998cited by this paper
• Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage/microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factor‐α in the central nervous system

  1997cited by this paper
• Mechanisms of angiogenesis

  1997cited by this paper
• Astrocyte-specific but not neuron-specific transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice.

  1997cited by this paper
• Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease.

  1996cited by this paper
• Cytokines in inflammatory brain lesions: helpful and harmful.

  1996cited by this paper
• Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model.

  1996cited by this paper
• Leukocyte-endothelial adhesion and angiogenesis in tumors

  1996cited by this paper
• Targeted CNS Expression of Interferon-γ in Transgenic Mice Leads to Hypomyelination, Reactive Gliosis, and Abnormal Cerebellar Development

  1996cited by this paper
• Microglia: a sensor for pathological events in the CNS.

  1996cited by this paper
• Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with parkinson's disease.

  1996cited by this paper
• Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease

  1996cited by this paper
• Endotoxin-induced appearance of immunoreactive interleukin-1 beta in ramified microglia in rat brain: a light and electron microscopic study.

  1995cited by this paper
• Cytokine-induced expression of vascular cell adhesion molecule-1 (VCAM-1) by astrocytes and astrocytoma cell lines.

  1995cited by this paper
• Cytokines and the nervous system II: Actions and mechanisms of action.

  1995cited by this paper
• Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity

  1995cited by this paper
• Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients

  1995cited by this paper
• Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia

  1995cited by this paper
• Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.

  1995cited by this paper
• Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

  1995cited by this paper
• Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients.

  1994cited by this paper
• Transgenic mice expressing IFN-gamma in the retina develop inflammation of the eye and photoreceptor loss.

  1994cited by this paper
• Do Chemokines Mediate Inflammatory Cell Invasion of the Central Nervous System Parenchyma?

  1994influential reference
• Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease.

  1994cited by this paper
• Oxidative stress: free radical production in neural degeneration.

  1994cited by this paper
• Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients

  1994cited by this paper
• CR3/43, a marker for activated human microglia: application to diagnostic neuropathology

  1994cited by this paper
• gamma Interferon expression disrupts lens and retinal differentiation in transgenic mice.

  1994cited by this paper
• Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta.

  1993cited by this paper
• Modulation of interferon-gamma-induced major histocompatibility complex class II and Fc receptor expression on isolated microglia by transforming growth factor-beta 1, interleukin-4, noradrenaline and glucocorticoids.

  1993cited by this paper
• Demonstration of interleukin-1β in Lewis rat brain during experimental allergic encephalomyelitis by immunocytochemistry at the light and ultrastructural level

  1993cited by this paper
• Interleukin‐6 and Transforming Growth Factor‐β1 mRNAs are Induced in Rat Facial Nucleus Following Motoneuron Axotomy

  1993cited by this paper
• Cytokine expression of macrophages in HIV‐1‐associated vacuolar myelopathy

  1993cited by this paper
• Differential effect of transforming growth factor β on the synthesis of Th1‐ and Th2‐like lymphokines by human T lymphocytes

  1992cited by this paper
• Tumor necrosis factor alpha induces adhesion molecule expression on human fetal astrocytes

  1992influential reference
• Migration of Hematogenous Cells Through the Blood‐Brain Barrier and the Initiation of CNS Inflammation

  1991cited by this paper
• Tumor necrosis factor Characterization at the molecular, cellular and in vivo level

  1991influential reference
• Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease

  1989cited by this paper
• Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

  1988cited by this paper
• Interleukin-1 stimulation of astroglial proliferation after brain injury.

  1985cited by this paper

• Advances in Gene Therapy Approaches Targeting Neuro-inflammation in Neurodegenerative Diseases.

  2024cites this paper
• Neuromelanin: Its role in the pathogenesis of idiopathic Parkinson's disease and potential as a therapeutic target.

  2023cites this paper
• Inhibition of abnormal C/EBPβ/α‐Syn signaling pathway through activation of Nrf2 ameliorates Parkinson's disease‐like pathology

  2023cites this paper
• Improving work life balance among female educationists during the COVID-19 lockdown

  2023cites this paper
• TRIM9-Mediated Resolution of Neuroinflammation Confers Neuroprotection upon Ischemic Stroke in Mice

  2023cites this paper
• Antidepressant and Neuroprotective Effects of 3-Hydroxy Paroxetine, an Analog of Paroxetine in Rats

  2022cites this paper
• Exercise-Boosted Mitochondrial Remodeling in Parkinson’s Disease

  2022cites this paper
• Alcohol, inflammation, and blood-brain barrier function in health and disease across development.

  2022cites this paper
• Role of Specialized Pro-resolving Mediators in Reducing Neuroinflammation in Neurodegenerative Disorders

  2022cites this paper
• Suppression of abnormal α-synuclein expression by activation of BDNF transcription ameliorates Parkinson’s disease-like pathology

  2022cites this paper
• Feruloylated oligosaccharides ameliorate MPTP-induced neurotoxicity in mice by activating ERK/CREB/BDNF/TrkB signalling pathway.

  2022cites this paper
• Inhibition of repulsive guidance molecule-a protects dopaminergic neurons in a mouse model of Parkinson’s disease

  2021cites this paper
• Doxycycline Therapeutic Approach in Parkinson’s Disease and L-DOPA-Induced Dyskinesia

  2021cites this paper
• Potential treatment of Parkinson’s disease with omega-3 polyunsaturated fatty acids

  2020cites this paper
• The experimental evidence for photobiomodulation-induced cellular and behavioral changes in animal models of Parkinson’s disease: a template for translation to patients

  2019cites this paper
• TRIM9-Mediated Resolution of Neuroinflammation Confers Neuroprotectionupon Ischemic Stroke in Mice

  2019cites this paper
• Natural Antioxidant Anthocyanins—A Hidden Therapeutic Candidate in Metabolic Disorders with Major Focus in Neurodegeneration

  2019cites this paper
• YAKLAŞIMLAR NEUROINFLAMMATION MODIFYING APPROACHES IN PARKINSON ’ S DISEASE

  2018influential citation
• Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease

  2017influential citation
• Degeneration of Dopaminergic Neurons Due to Metabolic Alterations and Parkinson’s Disease

  2016cites this paper
• Near-infrared light treatment reduces astrogliosis in MPTP-treated monkeys

  2016cites this paper
• Influence of caffeine on 3,4‐methylenedioxymethamphetamine‐induced dopaminergic neuron degeneration and neuroinflammation is age‐dependent

  2016cites this paper
• l‐DOPA‐induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?

  2016cites this paper
• Metformin Prevented Dopaminergic Neurotoxicity Induced by 3,4-Methylenedioxymethamphetamine Administration

  2016cites this paper
• Étude des mouvements anormaux dans une population non sélectionnée de patients ambulatoires souffrant de schizophrénie

  2016cites this paper
• Effect of crowding, temperature and age on glia activation and dopaminergic neurotoxicity induced by MDMA in the mouse brain.

  2016cites this paper
• Evaluation of Antiparkinson’s activity of Uncaria rhynchophylla, Mentha aquatica and Banisteriopsis caapi-plants with Monoamine Oxidase-B (MAO-B) inhibition potential.

  2015cites this paper
• Echinacoside Protects against 6-Hydroxydopamine-Induced Mitochondrial Dysfunction and Inflammatory Responses in PC12 Cells via Reducing ROS Production

  2015cites this paper
• Oxidative stress and Parkinson’s disease

  2015cites this paper
• Erratum to: MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex

  2014cites this paper
• Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease.

  2014cites this paper
• MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex

  2014cites this paper
• PACAP Protects Against Inflammatory-Mediated Toxicity in Dopaminergic SH-SY5Y Cells: Implication for Parkinson’s Disease

  2014cites this paper
• Neuroinflammation and Parkinson’s Disease

  2014cites this paper
• Structure and Biological Activity of Natural Melanin Pigments

  2013cites this paper
• Anti-inflammatory effects of lipoic acid through inhibition of GSK-3β in lipopolysaccharide-induced BV-2 microglial cells.

  2013cites this paper
• The MPTP/probenecid model of progressive Parkinson's disease.

  2013cites this paper
• Modeling early Parkinson's disease pathology with chronic low dose MPTP treatment

  2013cites this paper
• MPTP‐induced dopamine neuron degeneration and glia activation is potentiated in MDMA‐pretreated mice

  2013cites this paper
• Animal Models of Idiosyncratic, Drug-Induced Liver Injury: Emphasis on the Inflammatory Stress Hypothesis

  2012cites this paper
• Potential of D‐cycloserine in the treatment of behavioral and neuroinflammatory disorders in Parkinson's disease and studies that need to be performed before clinical trials

  2012cites this paper
• Prospects for New Treatment Options in Neurodegenerative Diseases

  2012cites this paper
• Mapping Brain Metals to Evaluate Therapies for Neurodegenerative Disease

  2011cites this paper
• Identifying candidate genes for Parkinson's disease by integrative genomics method.

  2011cites this paper
• The Role of Neuroinflammation in Parkinson's Disease

  2011cites this paper
• Iden ti fyi ng can di da te genes for Par kin son's disea se by integ ra ti ve geno mi cs met hod

  2011cites this paper
• Age-related changes in glial cells of dopamine midbrain subregions in rhesus monkeys.

  2010cites this paper
• Glia as a turning point in the therapeutic strategy of Parkinson's disease.

  2010cites this paper
• Altered Regulation of CD200 Receptor in Monocyte-Derived Macrophages from Individuals with Parkinson’s Disease

  2010cites this paper
• Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention.

  2010cites this paper
• Genetics of Parkinson's disease - with focus on genes of relevance for inflammation and dopamine neruon development

  2010cites this paper
• MPTP administration increases plasma levels of acute phase proteins in non-human primates (Macaca fascicularis).

  2009cites this paper
• PPAR‐gamma‐mediated neuroprotection in a chronic mouse model of Parkinson’s disease

  2009cites this paper
• Occupational factors and risk of Parkinson's disease: A population-based case-control study.

  2009cites this paper
• Novel mechanisms and approaches in the study of neurodegeneration and neuroprotection. A review

  2009cites this paper
• Design of pH-independent extended release matrix tablets of minocycline hydrochloride for the treatment of dementia

  2009cites this paper
• Inflammatory response in Parkinsonism.

  2009cites this paper
• Progressive Dopaminergic Degeneration in the Chronic MPTPp Mouse Model of Parkinson’s Disease

  2009cites this paper
• Neurotoxins and neurotoxic species implicated in neurodegeneration

  2009cites this paper
• Macrophages, Microglia, and Dendritic C

  2008cites this paper
• The effects of MPTP on the activation of microglia/astrocytes and cytokine/chemokine levels in different mice strains.

  2008cites this paper
• Glial reactions in Parkinson's disease

  2008cites this paper
• The alpha-synuclein burden hypothesis of Parkinson disease and its relationship to Alzheimer disease.

  2008cites this paper
• Influence of Age and Gender on Cytokine Expression in a Murine Model of Parkinson’s Disease

  2008cites this paper
• Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.

  2007cites this paper
• Osteopontin expression in activated glial cells following mechanical- or toxin-induced nigral dopaminergic cell loss.

  2007cites this paper
• Blood–Brain Barrier Pathology in Alzheimer's and Parkinson's Disease: Implications for Drug Therapy

  2007cites this paper
• Temporal mRNA profiles of inflammatory mediators in the murine MPTP model of Parkinson’s disease

  2007cites this paper
• Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits

  2007cites this paper
• Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease.

  2007cites this paper
• Activation of the p38MAPK cascade is associated with upregulation of TNF alpha receptors in the spinal motor neurons of mouse models of familial ALS.

  2006cites this paper
• Behavioral and morphological effects of minocycline in the 6-hydroxydopamine rat model of Parkinson's disease.

  2006cites this paper
• The pathogenesis of cell death in Parkinson's disease

  2006cites this paper
• Neuroinflammation: a potential therapeutic target

  2005cites this paper
• Brain, aging and neurodegeneration: role of zinc ion availability.

  2005cites this paper
• In mice, production of plasma IL-1 and IL-6 in response to MPTP is related to behavioral lateralization.

  2005cites this paper
• Triptolide protects dopaminergic neurons from inflammation-mediated damage induced by lipopolysaccharide intranigral injection.

  2005cites this paper
• Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor.

  2004cites this paper
• Antiapoptotic effects of budipine

  2004cites this paper